Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease

Completed · Not applicable

Conditions studied: Ulcerative Colitis, Crohn's Disease

In brief

The hypothesis underlying this study is that nasally administered calcitonin will stabilize or improve bone mineral density in young patients with ulcerative colitis or Crohn's disease. Patients who participate will receive either calcitonin or placebo and will have their bone mineral density measured at the start, at nine months, and at 18 months of study. Participants will also receive age appropriate doses of vitamin D and calcium supplements. Other serological measures of vitamin D status will be obtained every 3 months during the study.

Key facts

Study ID

NCT00114803

Run by

Boston Children's Hospital

People needed

66

Starts

2004-01-01

Expected to finish

2006-10-01

Last updated by the study team

2007-12-05

Who can join

Age: 8 and older, up to 22. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Low bone mineral density as defined
• Age 8 to 22 years
• Diagnosis of Crohn's disease or ulcerative colitis

You may not qualify if…

• Receiving calcitonin or biphosphonates, androgens or growth hormone
• Steroid induced fracture in the past
• Pregnant
• Diagnosis of kidney failure, polycystic ovaries syndrome, or malignancy

Where it is running

• Children's Hospital Boston — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.